Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020
07/23/2020 - 08:30 AM
SAN DIEGO , July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020 .
Date
Tuesday, August 4, 2020
Time
11:00 a.m. EDT (8:00 a.m. PDT)
Dial-in numbers
(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID
5884198
Webcast (live and archived)
www.evofem.com under "Investors " or click here
The live webcast and related slide presentation can be accessed on the Company's Investor page at https://evofem.investorroom.com/events . Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 10 minutes prior to the start of the call.
A telephone replay will be available approximately two hours after the call through Friday, August 7, 2020 at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 5884198. The webcast will be archived at https://evofem.investorroom.com/events .
About Evofem Biosciences, Inc. Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.
Contact Investor Relations Amy Raskopf araskopf@evofem.com
Media Cara Miller cmiller@evofem.com
http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2020-results-and-provide-corporate-update-on-tuesday-august-4-2020-301098441.html
SOURCE Evofem Biosciences, Inc.
EVFM Rankings
N/A Ranked by Stock Gains
EVFM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About EVFM
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
